{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:22:09Z","timestamp":1773796929156,"version":"3.50.1"},"publisher-location":"Cham","reference-count":148,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031803956","type":"print"},{"value":"9783031803963","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-80396-3_11","type":"book-chapter","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:59:50Z","timestamp":1742356790000},"page":"267-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients"],"prefix":"10.1007","author":[{"given":"Friedhelm","family":"Raue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Frank-Raue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"11","key":"11_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1445-2197.2010.05350.x","volume":"80","author":"D Abraham","year":"2010","unstructured":"Abraham D, Delbridge L, Clifton-Bligh R, Clifton-Bligh P, Grodski S, Robinson BG et al (2010) Medullary thyroid carcinoma presenting with an initial CEA elevation. ANZ J Surg 80(11):831\u2013833. https:\/\/doi.org\/10.1111\/j.1445-2197.2010.05350.x","journal-title":"ANZ J Surg"},{"issue":"2","key":"11_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.20945\/2359-3997000000112","volume":"63","author":"F Andrade","year":"2019","unstructured":"Andrade F, Rondeau G, Boucai L, Zeuren R, Shaha AR, Ganly I et al (2019) Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer. Arch Endocrinol Metab 63(2):137\u2013141. https:\/\/doi.org\/10.20945\/2359-3997000000112","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"11_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1245\/s10434-014-4109-4","volume":"22","author":"CJ Balentine","year":"2015","unstructured":"Balentine CJ, Chen H (2015) Chasing calcitonin: reoperations for medullary thyroid carcinoma. Ann Surg Oncol 22(1):7\u20138. https:\/\/doi.org\/10.1245\/s10434-014-4109-4","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"11_CR4","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1210\/jc.2005-0044","volume":"90","author":"J Barbet","year":"2005","unstructured":"Barbet J, Campion L, Kraeber-Bod\u00e9r\u00e9 F, Chatal JF, GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90(11):6077\u20136084. https:\/\/doi.org\/10.1210\/jc.2005-0044","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"11_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/thy.1996.6.305","volume":"6","author":"J Brierley","year":"1996","unstructured":"Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305\u2013310. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8875751","journal-title":"Thyroid"},{"issue":"2","key":"11_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2008.02.001","volume":"37","author":"JD Brierley","year":"2008","unstructured":"Brierley JD, Tsang RW (2008) External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin N Am 37(2):497\u2013509., xi. https:\/\/doi.org\/10.1016\/j.ecl.2008.02.001","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"3","key":"11_CR7","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2013.e37","volume":"5","author":"JA Call","year":"2013","unstructured":"Call JA, Caudill JS, McIver B, Foote RL (2013) A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors 5(3):e37. https:\/\/doi.org\/10.4081\/rt.2013.e37","journal-title":"Rare Tumors"},{"issue":"1","key":"11_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12149-017-1213-0","volume":"32","author":"F Caobelli","year":"2018","unstructured":"Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, Scalorbi F, Donner D, Alongi P, Young AIMN Working Group (2018) Predictive and prognostic value of 18F-DOPA PET\/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med 32(1):7\u201315. https:\/\/doi.org\/10.1007\/s12149-017-1213-0","journal-title":"Ann Nucl Med"},{"issue":"2","key":"11_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2023.0482","volume":"34","author":"S Censi","year":"2024","unstructured":"Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I et al (2024) Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma. Thyroid 34(2):177\u2013185. https:\/\/doi.org\/10.1089\/thy.2023.0482","journal-title":"Thyroid"},{"issue":"11","key":"11_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","volume":"24","author":"JF Chatal","year":"2006","unstructured":"Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J, French Endocrine Tumor Group (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French endocrine tumor group. J Clin Oncol 24(11):1705\u20131711. https:\/\/doi.org\/10.1200\/JCO.2005.04.4917","journal-title":"J Clin Oncol"},{"issue":"3","key":"11_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009686","volume":"97","author":"JB Choi","year":"2018","unstructured":"Choi JB, Lee SG, Kim MJ, Kim TH, Ban EJ, Lee CR et al (2018) Dynamic risk stratification in medullary thyroid carcinoma: single institution experiences. Medicine (Baltimore) 97(3):e9686. https:\/\/doi.org\/10.1097\/MD.0000000000009686","journal-title":"Medicine (Baltimore)"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","volume":"20","author":"R Ciampi","year":"2019","unstructured":"Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V et al (2019) Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20:324\u2013336. https:\/\/doi.org\/10.1016\/j.isci.2019.09.030","journal-title":"iScience"},{"issue":"5","key":"11_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/SLA.0b013e31813e66b9","volume":"246","author":"K Cupisti","year":"2007","unstructured":"Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution\u2019s experience over 20 years. Ann Surg 246(5):815\u2013821. https:\/\/doi.org\/10.1097\/SLA.0b013e31813e66b9","journal-title":"Ann Surg"},{"issue":"6","key":"11_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2265.2006.02659.x","volume":"65","author":"JW de Groot","year":"2006","unstructured":"de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65(6):729\u2013736. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02659.x","journal-title":"Clin Endocrinol"},{"issue":"9","key":"11_CR15","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1210\/jc.2007-0649","volume":"92","author":"JW de Groot","year":"2007","unstructured":"de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92(9):3466\u20133469. https:\/\/doi.org\/10.1210\/jc.2007-0649","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"11_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s12020-018-1706-1","volume":"62","author":"LH de Vries","year":"2018","unstructured":"de Vries LH, Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ et al (2018) SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine 62(3):639\u2013647. https:\/\/doi.org\/10.1007\/s12020-018-1706-1","journal-title":"Endocrine"},{"issue":"1","key":"11_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/thy.2022.0295","volume":"33","author":"M Duval","year":"2023","unstructured":"Duval M, Ferreira CV, Marmitt L, Dora JM, Espindola M, Benini AF et al (2023) An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: results of a retrospective cohort study. Thyroid 33(1):82\u201390. https:\/\/doi.org\/10.1089\/thy.2022.0295","journal-title":"Thyroid"},{"issue":"2","key":"11_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"11_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1210\/jc.2003-030550","volume":"89","author":"R Elisei","year":"2004","unstructured":"Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89(1):163\u2013168. https:\/\/doi.org\/10.1210\/jc.2003-030550","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"11_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1210\/jc.2007-1714","volume":"93","author":"R Elisei","year":"2008","unstructured":"Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93(3):682\u2013687. https:\/\/doi.org\/10.1210\/jc.2007-1714","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"11_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrendo.2012.38","volume":"8","author":"R Elisei","year":"2012","unstructured":"Elisei R, Pinchera A (2012) Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 8(8):466\u2013475. https:\/\/doi.org\/10.1038\/nrendo.2012.38","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"11_CR22","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1210\/jc.2007-1005","volume":"92","author":"R Elisei","year":"2007","unstructured":"Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E et al (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725\u20134729. https:\/\/doi.org\/10.1210\/jc.2007-1005","journal-title":"J Clin Endocrinol Metab"},{"issue":"29","key":"11_CR23","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639\u20133646. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659","journal-title":"J Clin Oncol"},{"issue":"3","key":"11_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/gcc.2870120308","volume":"12","author":"C Eng","year":"1995","unstructured":"Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F et al (1995) Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12(3):209\u2013212. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7536460","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"11_CR25","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/bjs\/znab106","volume":"108","author":"F Fanget","year":"2021","unstructured":"Fanget F, Demarchi MS, Maillard L, Lintis A, Decaussin M, Lifante JC (2021) Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg 108(9):1064\u20131071. https:\/\/doi.org\/10.1093\/bjs\/znab106","journal-title":"Br J Surg"},{"issue":"5","key":"11_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00268-007-9317-7","volume":"32","author":"E Fialkowski","year":"2008","unstructured":"Fialkowski E, DeBenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32(5):754\u2013765. https:\/\/doi.org\/10.1007\/s00268-007-9317-7","journal-title":"World J Surg"},{"issue":"2","key":"11_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/eje.1.02216","volume":"155","author":"K Frank-Raue","year":"2006","unstructured":"Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155(2):229\u2013236. https:\/\/doi.org\/10.1530\/eje.1.02216","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"11_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/EJE-06-0695","volume":"157","author":"K Frank-Raue","year":"2007","unstructured":"Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F (2007) Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157(2):215\u2013220. https:\/\/doi.org\/10.1530\/EJE-06-0695","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"11_CR29","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/jc.2005-2401","volume":"91","author":"J Fromigue","year":"2006","unstructured":"Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M (2006) Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 91(7):2496\u20132499. https:\/\/doi.org\/10.1210\/jc.2005-2401","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13044-017-0041-6","volume":"10","author":"G Geller","year":"2017","unstructured":"Geller G, Laskin J, Cheung WY, Ho C (2017) A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res 10:6. https:\/\/doi.org\/10.1186\/s13044-017-0041-6","journal-title":"Thyroid Res"},{"issue":"6","key":"11_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0039-6060(97)90217-8","volume":"122","author":"O Gimm","year":"1997","unstructured":"Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122(6):1124\u20131130; discussion 1130-1121. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9426428","journal-title":"Surgery"},{"issue":"1","key":"11_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M (2020) EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 47(1):61\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04458-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"11_CR33","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"AL Giraudet","year":"2007","unstructured":"Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L et al (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185\u20134190. https:\/\/doi.org\/10.1210\/jc.2007-1211","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"11_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1210\/jc.2002-021354","volume":"88","author":"L Gourgiotis","year":"2003","unstructured":"Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K (2003) Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88(2):637\u2013641. https:\/\/doi.org\/10.1210\/jc.2002-021354","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"11_CR35","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/jcm9113507","volume":"9","author":"E Grossrubatscher","year":"2020","unstructured":"Grossrubatscher E, Fanciulli G, Pes L, Sesti F, Dolci C, de Cicco F et al (2020) Advances in the Management of Medullary Thyroid Carcinoma: focus on peptide receptor radionuclide therapy. J Clin Med 9(11):3507. https:\/\/doi.org\/10.3390\/jcm9113507","journal-title":"J Clin Med"},{"issue":"3","key":"11_CR36","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1210\/jc.2014-4153","volume":"100","author":"EG Grubbs","year":"2015","unstructured":"Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE et al (2015) RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 100(3):788\u2013793. https:\/\/doi.org\/10.1210\/jc.2014-4153","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"11_CR37","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M et al (2023) Phase 3 trial of Selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 389(20):1851\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"issue":"1","key":"11_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","volume":"4","author":"J Hadoux","year":"2016","unstructured":"Hadoux J, Pacini F, Tuttle RM, Schlumberger M (2016) Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol 4(1):64\u201371. https:\/\/doi.org\/10.1016\/S2213-8587(15)00337-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"11_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000445978","volume":"90","author":"AM Heilmann","year":"2016","unstructured":"Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J et al (2016) Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology 90(6):339\u2013346. https:\/\/doi.org\/10.1159\/000445978","journal-title":"Oncology"},{"issue":"1","key":"11_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28(1):64\u201371. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11202454","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"11_CR41","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.21037\/tcr-21-1179","volume":"10","author":"S Huang","year":"2021","unstructured":"Huang S, Zhong J, Zhang Z, Chen R, Li J, Sun J, Chen H (2021) Prognosis of radiotherapy in medullary thyroid carcinoma patients without distant metastasis. Transl Cancer Res 10(11):4714\u20134726. https:\/\/doi.org\/10.21037\/tcr-21-1179","journal-title":"Transl Cancer Res"},{"issue":"2","key":"11_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1677\/erc.0.0110357","volume":"11","author":"SI Ismailov","year":"2004","unstructured":"Ismailov SI, Piulatova NR (2004) Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11(2):357\u2013363. https:\/\/doi.org\/10.1677\/erc.0.0110357","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"11_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.38.17","volume":"38","author":"T Isozaki","year":"1999","unstructured":"Isozaki T, Kiba T, Numata K, Saito S, Shimamura T, Kitamura T et al (1999) Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med 38(1):17\u201321. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10052736","journal-title":"Intern Med"},{"issue":"22 Pt 1","key":"11_CR44","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"F Iten","year":"2007","unstructured":"Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR et al (2007) Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13(22 Pt 1):6696\u20136702. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0935","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0194599820947696","volume":"164","author":"M Jin","year":"2021","unstructured":"Jin M, Megwalu UC, Noel JE (2021) External beam radiotherapy for medullary thyroid cancer following Total or near-Total thyroidectomy. Otolaryngol Head Neck Surg 164(1):97\u2013103. https:\/\/doi.org\/10.1177\/0194599820947696","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"11_CR46","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","volume":"88","author":"E Kebebew","year":"2000","unstructured":"Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000a) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139\u20131148. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10699905","journal-title":"Cancer"},{"issue":"8","key":"11_CR47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archsurg.135.8.895","volume":"135","author":"E Kebebew","year":"2000","unstructured":"Kebebew E, Kikuchi S, Duh QY, Clark OH (2000b) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135(8):895\u2013901. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10922248","journal-title":"Arch Surg"},{"issue":"4","key":"11_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.107.047720","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ et al (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49(4):524\u2013531. https:\/\/doi.org\/10.2967\/jnumed.107.047720","journal-title":"J Nucl Med"},{"issue":"4","key":"11_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/thy.2020.0167","volume":"31","author":"A Kotwal","year":"2021","unstructured":"Kotwal A, Erickson D, Geske JR, Hay ID, Castro MR (2021) Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades. Thyroid 31(4):616\u2013626. https:\/\/doi.org\/10.1089\/thy.2020.0167","journal-title":"Thyroid"},{"issue":"6","key":"11_CR50","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0039","volume":"134","author":"MA Kouvaraki","year":"2003","unstructured":"Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R et al (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946\u2013954; discussion 954-945. https:\/\/doi.org\/10.1016\/S0039","journal-title":"Surgery"},{"issue":"2","key":"11_CR51","first-page":"247","volume":"47","author":"F Kraeber-Bodere","year":"2006","unstructured":"Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47(2):247\u2013255. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16455630","journal-title":"J Nucl Med"},{"issue":"1","key":"11_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EC-19-0387","volume":"9","author":"A Kukulska","year":"2019","unstructured":"Kukulska A, Krajewska J, Kolosza Z, Paliczka-Cieslik E, Kropinska A, Pawlaczek A et al (2019) The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma. Endocr Connect 9(1):1\u20138. https:\/\/doi.org\/10.1530\/EC-19-0387","journal-title":"Endocr Connect"},{"issue":"1","key":"11_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamasurg.2017.3555","volume":"153","author":"EJ Kuo","year":"2018","unstructured":"Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ (2018) Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg 153(1):52\u201359. https:\/\/doi.org\/10.1001\/jamasurg.2017.3555","journal-title":"JAMA Surg"},{"issue":"19","key":"11_CR54","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660\u20132666. https:\/\/doi.org\/10.1200\/JCO.2010.32.4145","journal-title":"J Clin Oncol"},{"key":"11_CR55","doi-asserted-by":"publisher","first-page":"1893047","DOI":"10.1155\/2019\/1893047","volume":"2019","author":"SV Kushchayev","year":"2019","unstructured":"Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM (2019) Medullary thyroid carcinoma: an update on imaging. J Thyroid Res 2019:1893047. https:\/\/doi.org\/10.1155\/2019\/1893047","journal-title":"J Thyroid Res"},{"issue":"1","key":"11_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12020-015-0849-6","volume":"53","author":"H Kwon","year":"2016","unstructured":"Kwon H, Kim WG, Jeon MJ, Song DE, Lee YM, Sung TY et al (2016) Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine 53(1):174\u2013181. https:\/\/doi.org\/10.1007\/s12020-015-0849-6","journal-title":"Endocrine"},{"issue":"14","key":"11_CR57","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","volume":"28","author":"ET Lam","year":"2010","unstructured":"Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323\u20132330. https:\/\/doi.org\/10.1200\/JCO.2009.25.0068","journal-title":"J Clin Oncol"},{"issue":"2","key":"11_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1530\/EJE-07-0667","volume":"158","author":"A Laure Giraudet","year":"2008","unstructured":"Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158(2):239\u2013246. https:\/\/doi.org\/10.1530\/EJE-07-0667","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"11_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/RLU.0000000000002940","volume":"45","author":"SW Lee","year":"2020","unstructured":"Lee SW, Shim SR, Jeong SY, Kim SJ (2020) Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin Nucl Med 45(5):341\u2013348. https:\/\/doi.org\/10.1097\/RLU.0000000000002940","journal-title":"Clin Nucl Med"},{"issue":"12","key":"11_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1055\/s-0042-118181","volume":"48","author":"G Leidig-Bruckner","year":"2016","unstructured":"Leidig-Bruckner G, Bruckner T, Raue F, Frank-Raue K (2016) Long-term follow-up and treatment of postoperative permanent hypoparathyroidism in patients with medullary thyroid carcinoma: differences in complete and partial disease. Horm Metab Res 48(12):806\u2013813. https:\/\/doi.org\/10.1055\/s-0042-118181","journal-title":"Horm Metab Res"},{"issue":"2","key":"11_CR61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/thy.2014.0277","volume":"25","author":"SC Lindsey","year":"2015","unstructured":"Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 25(2):242\u2013249. https:\/\/doi.org\/10.1089\/thy.2014.0277","journal-title":"Thyroid"},{"issue":"6","key":"11_CR62","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.surg.2005.09.020","volume":"138","author":"K Lorenz","year":"2005","unstructured":"Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138(6):986\u2013993; discussion 993. https:\/\/doi.org\/10.1016\/j.surg.2005.09.020","journal-title":"Surgery"},{"issue":"6","key":"11_CR63","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1210\/jc.2009-2368","volume":"95","author":"A Machens","year":"2010","unstructured":"Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655\u20132663. https:\/\/doi.org\/10.1210\/jc.2009-2368","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"11_CR64","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/SLA.0b013e31826bc239","volume":"257","author":"A Machens","year":"2013","unstructured":"Machens A, Dralle H (2013a) Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 257(4):751\u2013757. https:\/\/doi.org\/10.1097\/SLA.0b013e31826bc239","journal-title":"Ann Surg"},{"issue":"2","key":"11_CR65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/SLA.0b013e318268301d","volume":"257","author":"A Machens","year":"2013","unstructured":"Machens A, Dralle H (2013b) Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg 257(2):323\u2013329. https:\/\/doi.org\/10.1097\/SLA.0b013e318268301d","journal-title":"Ann Surg"},{"issue":"4","key":"11_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/bjs.11071","volume":"106","author":"A Machens","year":"2019","unstructured":"Machens A, Lorenz K, Dralle H (2019) Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer. Br J Surg 106(4):412\u2013418. https:\/\/doi.org\/10.1002\/bjs.11071","journal-title":"Br J Surg"},{"issue":"6","key":"11_CR67","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/bjs.11444","volume":"107","author":"A Machens","year":"2020","unstructured":"Machens A, Lorenz K, Dralle H (2020) Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg 107(6):695\u2013704. https:\/\/doi.org\/10.1002\/bjs.11444","journal-title":"Br J Surg"},{"issue":"16","key":"11_CR68","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa012915","volume":"349","author":"A Machens","year":"2003","unstructured":"Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H, European Multiple Endocrine Neoplasia (EUROMEN) Study Group (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517\u20131525. https:\/\/doi.org\/10.1056\/NEJMoa012915","journal-title":"N Engl J Med"},{"issue":"4","key":"11_CR69","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1210\/jc.2004-1836","volume":"90","author":"A Machens","year":"2005","unstructured":"Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90(4):2029\u20132034. https:\/\/doi.org\/10.1210\/jc.2004-1836","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"11_CR70","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","volume":"21","author":"Z Maghsoomi","year":"2021","unstructured":"Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME (2021) Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer 21(1):579. https:\/\/doi.org\/10.1186\/s12885-021-08257-x","journal-title":"BMC Cancer"},{"issue":"2","key":"11_CR71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","volume":"33","author":"C Mahler","year":"1990","unstructured":"Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33(2):261\u2013269. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1977536","journal-title":"Clin Endocrinol"},{"issue":"6","key":"11_CR72","first-page":"1241","volume":"56","author":"DJ Marsh","year":"1996","unstructured":"Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R et al (1996a) Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 56(6):1241\u20131243. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8640806","journal-title":"Cancer Res"},{"issue":"3","key":"11_CR73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-2265.1996.681503.x","volume":"44","author":"DJ Marsh","year":"1996","unstructured":"Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL et al (1996b) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44(3):249\u2013257. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8729519","journal-title":"Clin Endocrinol"},{"issue":"2","key":"11_CR74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jso.21557","volume":"102","author":"SR Martinez","year":"2010","unstructured":"Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102(2):175\u2013178. https:\/\/doi.org\/10.1002\/jso.21557","journal-title":"J Surg Oncol"},{"issue":"3","key":"11_CR75","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/thy.2018.0564","volume":"29","author":"JS Mathiesen","year":"2019","unstructured":"Mathiesen JS, Kroustrup JP, Vestergaard P, Stochholm K, Poulsen PL, Rasmussen AK et al (2019) Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: a Nationwide study. Thyroid 29(3):368\u2013377. https:\/\/doi.org\/10.1089\/thy.2018.0564","journal-title":"Thyroid"},{"key":"11_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.864253","volume":"13","author":"A Matrone","year":"2022","unstructured":"Matrone A, Gambale C, Prete A, Elisei R (2022) Sporadic medullary thyroid carcinoma: towards a precision medicine. Front Endocrinol (Lausanne) 13:864253. https:\/\/doi.org\/10.3389\/fendo.2022.864253","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"11_CR77","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-12-0943","volume":"168","author":"JA Meijer","year":"2013","unstructured":"Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT et al (2013) Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol 168(5):779\u2013786. https:\/\/doi.org\/10.1530\/EJE-12-0943","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"11_CR78","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","volume":"72","author":"JA Meijer","year":"2010","unstructured":"Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA, Smit JW (2010) Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72(4):534\u2013542. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03666.x","journal-title":"Clin Endocrinol"},{"issue":"1","key":"11_CR79","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013884","volume":"98","author":"K Meng","year":"2019","unstructured":"Meng K, Luo H, Chen H, Guo H, Xia W (2019) Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: a population-based study using the SEER 18 database. Medicine (Baltimore) 98(1):e13884. https:\/\/doi.org\/10.1097\/MD.0000000000013884","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"11_CR80","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1530\/EJE-11-0079","volume":"164","author":"C Mian","year":"2011","unstructured":"Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F et al (2011) Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164(6):971\u2013976. https:\/\/doi.org\/10.1530\/EJE-11-0079","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"11_CR81","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1210\/jc.2004-1500","volume":"90","author":"E Mirallie","year":"2005","unstructured":"Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L et al (2005) High frequency of bone\/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90(2):779\u2013788. https:\/\/doi.org\/10.1210\/jc.2004-1500","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"11_CR82","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s00268-018-4789-1","volume":"43","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Kudo T, Kihara M, Oda H, Ito Y, Miya A (2019) Spontaneous deceleration and acceleration of growth rate in medullary thyroid carcinomas suggested by changes in calcitonin doubling times over long-term surveillance. World J Surg 43(2):504\u2013512. https:\/\/doi.org\/10.1007\/s00268-018-4789-1","journal-title":"World J Surg"},{"issue":"3","key":"11_CR83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","volume":"48","author":"E Modigliani","year":"1998","unstructured":"Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC study group. Groupe d\u2019etude des tumeurs a calcitonine. Clin Endocrinol 48(3):265\u2013273. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9578814","journal-title":"Clin Endocrinol"},{"issue":"5","key":"11_CR84","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00268-006-0846-2","volume":"31","author":"JF Moley","year":"2007","unstructured":"Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31(5):946\u2013956. https:\/\/doi.org\/10.1007\/s00268-006-0846-2","journal-title":"World J Surg"},{"issue":"11","key":"11_CR85","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","volume":"100","author":"MM Moura","year":"2009","unstructured":"Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO et al (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777\u20131783. https:\/\/doi.org\/10.1038\/sj.bjc.6605056","journal-title":"Br J Cancer"},{"issue":"5","key":"11_CR86","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1210\/jc.2010-1921","volume":"96","author":"MM Moura","year":"2011","unstructured":"Moura MM, Cavaco BM, Pinto AE, Leite V (2011) High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96(5):E863\u2013E868. https:\/\/doi.org\/10.1210\/jc.2010-1921","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"11_CR87","doi-asserted-by":"publisher","first-page":"R251","DOI":"10.1530\/EC-20-0374","volume":"9","author":"M Oczko-Wojciechowska","year":"2020","unstructured":"Oczko-Wojciechowska M, Czarniecka A, Gawlik T, Jarzab B, Krajewska J (2020) Current status of the prognostic molecular markers in medullary thyroid carcinoma. Endocr Connect 9(12):R251\u2013R263. https:\/\/doi.org\/10.1530\/EC-20-0374","journal-title":"Endocr Connect"},{"issue":"4","key":"11_CR88","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2967\/jnumed.106.036681","volume":"48","author":"SC Ong","year":"2007","unstructured":"Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M et al (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48(4):501\u2013507. https:\/\/doi.org\/10.2967\/jnumed.106.036681","journal-title":"J Nucl Med"},{"issue":"1","key":"11_CR89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000493977","volume":"8","author":"EM Opsahl","year":"2019","unstructured":"Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI et al (2019) Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway: a Nationwide population-based study. Eur Thyroid J 8(1):31\u201340. https:\/\/doi.org\/10.1159\/000493977","journal-title":"Eur Thyroid J"},{"issue":"8","key":"11_CR90","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/oxfordjournals.annonc.a058984","volume":"5","author":"F Orlandi","year":"1994","unstructured":"Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5(8):763\u2013765. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7826911","journal-title":"Ann Oncol"},{"issue":"4","key":"11_CR91","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1245\/s10434-021-11158-9","volume":"29","author":"TJ Ow","year":"2022","unstructured":"Ow TJ, Mehta V, Kim S, Vakil M, Friedmann P, In H (2022) Evaluation of survival and postoperative radiation among patients with advanced medullary thyroid carcinoma: an analysis of the National Cancer Database. Ann Surg Oncol 29(4):2582\u20132591. https:\/\/doi.org\/10.1245\/s10434-021-11158-9","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"11_CR92","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","volume":"22","author":"F Pacini","year":"2010","unstructured":"Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):475\u2013485. https:\/\/doi.org\/10.1016\/j.clon.2010.05.002","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"11_CR93","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/thy.2014.0241","volume":"25","author":"K Pak","year":"2015","unstructured":"Pak K, Suh S, Kim SJ, Kim IJ (2015) Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid 25(1):63\u201370. https:\/\/doi.org\/10.1089\/thy.2014.0241","journal-title":"Thyroid"},{"issue":"12","key":"11_CR94","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/oncolo\/oyad232","volume":"28","author":"AJ Papachristos","year":"2023","unstructured":"Papachristos AJ, Nicholls LE, Mechera R, Aniss AM, Robinson B, Clifton-Bligh R et al (2023) Management of Medullary Thyroid Cancer: patterns of recurrence and outcomes of Reoperative surgery. Oncologist 28(12):1064\u20131071. https:\/\/doi.org\/10.1093\/oncolo\/oyad232","journal-title":"Oncologist"},{"issue":"18","key":"11_CR95","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.3390\/cancers13184670","volume":"13","author":"H Park","year":"2021","unstructured":"Park H, Yang H, Heo J, Kim TH, Kim SW, Chung JH (2021) Long-term outcomes and causes of death among medullary thyroid carcinoma patients with distant metastases. Cancers (Basel) 13(18):4670. https:\/\/doi.org\/10.3390\/cancers13184670","journal-title":"Cancers (Basel)"},{"issue":"6","key":"11_CR96","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/medicina57060609","volume":"57","author":"I Passos","year":"2021","unstructured":"Passos I, Stefanidou E, Meditskou-Eythymiadou S, Mironidou-Tzouveleki M, Manaki V, Magra V et al (2021) A review of the significance in measuring preoperative and postoperative carcinoembryonic antigen (CEA) values in patients with medullary thyroid carcinoma (MTC). Medicina (Kaunas) 57(6):609. https:\/\/doi.org\/10.3390\/medicina57060609","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"11_CR97","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","volume":"88","author":"G Pellegriti","year":"2003","unstructured":"Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88(10):1537\u20131542. https:\/\/doi.org\/10.1038\/sj.bjc.6600930","journal-title":"Br J Cancer"},{"issue":"8","key":"11_CR98","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1210\/clinem\/dgad061","volume":"108","author":"A Prete","year":"2023","unstructured":"Prete A, Gambale C, Torregrossa L, Ciampi R, Romei C, Ramone T et al (2023) Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment. J Clin Endocrinol Metab 108(8):e613\u2013e622. https:\/\/doi.org\/10.1210\/clinem\/dgad061","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"11_CR99","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/thy.2010.0248","volume":"22","author":"GM Quan","year":"2012","unstructured":"Quan GM, Pointillart V, Palussiere J, Bonichon F (2012) Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. Thyroid 22(2):125\u2013130. https:\/\/doi.org\/10.1089\/thy.2010.0248","journal-title":"Thyroid"},{"issue":"4","key":"11_CR100","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/gut.29.4.537","volume":"29","author":"JC Rambaud","year":"1988","unstructured":"Rambaud JC, Jian R, Flourie B, Hautefeuille M, Salmeron M, Thuillier F et al (1988) Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut 29(4):537\u2013543. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3371722","journal-title":"Gut"},{"issue":"1","key":"11_CR101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","volume":"161","author":"RW Randle","year":"2017","unstructured":"Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, Pitt SC (2017) Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 161(1):137\u2013146. https:\/\/doi.org\/10.1016\/j.surg.2016.04.053","journal-title":"Surgery"},{"issue":"5","key":"11_CR102","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s004230050143","volume":"383","author":"F Raue","year":"1998","unstructured":"Raue F (1998) German medullary thyroid carcinoma\/multiple endocrine neoplasia registry. German MTC\/MEN study group. Medullary thyroid carcinoma\/multiple endocrine neoplasia type 2. Langenbeck\u2019s Arch Surg 383(5):334\u2013336. https:\/\/doi.org\/10.1007\/s004230050143","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"9","key":"11_CR103","doi-asserted-by":"publisher","first-page":"e3582","DOI":"10.1210\/clinem\/dgab326","volume":"106","author":"F Raue","year":"2021","unstructured":"Raue F, Bruckner T, Frank-Raue K (2021) Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 106(9):e3582\u2013e3591. https:\/\/doi.org\/10.1210\/clinem\/dgab326","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"11_CR104","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2265.2008.03229.x","volume":"69","author":"G Rendl","year":"2008","unstructured":"Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 69(3):497\u2013505. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03229.x","journal-title":"Clin Endocrinol"},{"issue":"6","key":"11_CR105","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/jc.2009-2461","volume":"95","author":"BG Robinson","year":"2010","unstructured":"Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2664\u20132671. https:\/\/doi.org\/10.1210\/jc.2009-2461","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"11_CR106","doi-asserted-by":"publisher","first-page":"E509","DOI":"10.1210\/jc.2010-1234","volume":"96","author":"V Rohmer","year":"2011","unstructured":"Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, Chabrier G, Caron P, Rodien P, Schlumberger M, Baudin E, Groupe Fran\u00e7ais des Tumeurs Endocrines (2011) Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d\u2019Etude des Tumeurs endocrines. J Clin Endocrinol Metab 96(3):E509\u2013E518. https:\/\/doi.org\/10.1210\/jc.2010-1234","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"11_CR107","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9):2134\u20132142. https:\/\/doi.org\/10.1002\/cncr.22244","journal-title":"Cancer"},{"issue":"4","key":"11_CR108","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1210\/jcem.81.4.8636377","volume":"81","author":"C Romei","year":"1996","unstructured":"Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81(4):1619\u20131622. https:\/\/doi.org\/10.1210\/jcem.81.4.8636377","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"11_CR109","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1089\/thy.2011.0358","volume":"22","author":"C Romei","year":"2012","unstructured":"Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R et al (2012) Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22(5):476\u2013481. https:\/\/doi.org\/10.1089\/thy.2011.0358","journal-title":"Thyroid"},{"issue":"12","key":"11_CR110","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","volume":"44","author":"AR Romero-Lluch","year":"2017","unstructured":"Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vazquez R, Martinez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, Navarro-Gonzalez E (2017) Diagnostic utility of PET\/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging 44(12):2004\u20132013. https:\/\/doi.org\/10.1007\/s00259-017-3759-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"11_CR111","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1245\/s10434-014-4102-y","volume":"22","author":"KJ Rowland","year":"2015","unstructured":"Rowland KJ, Jin LX, Moley JF (2015) Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol 22(1):96\u2013102. https:\/\/doi.org\/10.1245\/s10434-014-4102-y","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"11_CR112","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ejso.2007.08.005","volume":"34","author":"D Rubello","year":"2008","unstructured":"Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S et al (2008) The role of 18F-FDG PET\/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 34(5):581\u2013586. https:\/\/doi.org\/10.1016\/j.ejso.2007.08.005","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"11_CR113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/EJE-14-0076","volume":"171","author":"K Saltiki","year":"2014","unstructured":"Saltiki K, Rentziou G, Stamatelopoulos K, Georgiopoulos G, Stavrianos C, Lambrinoudaki E, Alevizaki M (2014) Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur J Endocrinol 171(1):117\u2013126. https:\/\/doi.org\/10.1530\/EJE-14-0076","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"11_CR114","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","volume":"17","author":"D Salvatore","year":"2021","unstructured":"Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17(5):296\u2013306. https:\/\/doi.org\/10.1038\/s41574-021-00470-9","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"11_CR115","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1089\/thy.2007.0179","volume":"18","author":"L Santarpia","year":"2008","unstructured":"Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ (2008) Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid 18(8):901\u2013905. https:\/\/doi.org\/10.1089\/thy.2007.0179","journal-title":"Thyroid"},{"issue":"6","key":"11_CR116","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cen.12566","volume":"81","author":"P Santhanam","year":"2014","unstructured":"Santhanam P, Taieb D (2014) Role of (18) F-FDOPA PET\/CT imaging in endocrinology. Clin Endocrinol 81(6):789\u2013798. https:\/\/doi.org\/10.1111\/cen.12566","journal-title":"Clin Endocrinol"},{"issue":"1","key":"11_CR117","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF01612635","volume":"116","author":"H Scherubl","year":"1990","unstructured":"Scherubl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116(1):21\u201323. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2312602","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"11_CR118","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/1097-0215(20010120)95:1<62::aid-ijc1011>3.0.co;2-1","volume":"95","author":"T Schilling","year":"2001","unstructured":"Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W et al (2001) Prognostic value of codon 918 (ATG\u2014>ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95(1):62\u201366. https:\/\/doi.org\/10.1002\/1097-0215(20010120)95:1<62::aid-ijc1011>3.0.co;2-1","journal-title":"Int J Cancer"},{"issue":"2","key":"11_CR119","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/bjc.1995.73","volume":"71","author":"M Schlumberger","year":"1995","unstructured":"Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71(2):363\u2013365. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7530987","journal-title":"Br J Cancer"},{"issue":"23","key":"11_CR120","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","volume":"27","author":"MJ Schlumberger","year":"2009","unstructured":"Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794\u20133801. https:\/\/doi.org\/10.1200\/JCO.2008.18.7815","journal-title":"J Clin Oncol"},{"issue":"7","key":"11_CR121","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/hed.20791","volume":"30","author":"DL Schwartz","year":"2008","unstructured":"Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH et al (2008) Postoperative radiotherapy for advanced medullary thyroid cancer\u2014local disease control in the modern era. Head Neck 30(7):883\u2013888. https:\/\/doi.org\/10.1002\/hed.20791","journal-title":"Head Neck"},{"issue":"3","key":"11_CR122","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/0284186X.2015.1070963","volume":"55","author":"P Siironen","year":"2016","unstructured":"Siironen P, Hagstrom J, Maenpaa HO, Louhimo J, Arola J, Haglund C (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55(3):357\u2013364. https:\/\/doi.org\/10.3109\/0284186X.2015.1070963","journal-title":"Acta Oncol"},{"issue":"11","key":"11_CR123","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJMoa043999","volume":"353","author":"MA Skinner","year":"2005","unstructured":"Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353(11):1105\u20131113. https:\/\/doi.org\/10.1056\/NEJMoa043999","journal-title":"N Engl J Med"},{"issue":"1","key":"11_CR124","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/thy.2023.0363","volume":"34","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW et al (2024) Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study. Thyroid 34(1):26\u201340. https:\/\/doi.org\/10.1089\/thy.2023.0363","journal-title":"Thyroid"},{"issue":"5","key":"11_CR125","doi-asserted-by":"publisher","first-page":"532","DOI":"10.6004\/jnccn.2010.0041","volume":"8","author":"SA Terezakis","year":"2010","unstructured":"Terezakis SA, Lee NY (2010) The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Cancer Netw 8(5):532\u2013540; quiz 541. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20495083","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"11_CR126","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40463-018-0303-x","volume":"47","author":"S Turkdogan","year":"2018","unstructured":"Turkdogan S, Forest VI, Hier MP, Tamilia M, Florea A, Payne RJ (2018) Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. J Otolaryngol Head Neck Surg 47(1):55. https:\/\/doi.org\/10.1186\/s40463-018-0303-x","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"7","key":"11_CR127","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","volume":"49","author":"RM Tuttle","year":"2013","unstructured":"Tuttle RM, Ganly I (2013) Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 49(7):695\u2013701. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.03.443","journal-title":"Oral Oncol"},{"issue":"1","key":"11_CR128","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/EJE-18-1008","volume":"181","author":"O Twito","year":"2019","unstructured":"Twito O, Grozinsky-Glasberg S, Levy S, Bachar G, Gross DJ, Benbassat C et al (2019) Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study. Eur J Endocrinol 181(1):13\u201321. https:\/\/doi.org\/10.1530\/EJE-18-1008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"11_CR129","first-page":"549","volume":"23","author":"I Vainas","year":"2004","unstructured":"Vainas I, Koussis C, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I et al (2004) Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 23(4):549\u2013559. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15743023","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"11_CR130","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1245\/s10434-014-4115-6","volume":"22","author":"HH Verbeek","year":"2015","unstructured":"Verbeek HH, Meijer JA, Zandee WT, Kramp KH, Sluiter WJ, Smit JW et al (2015) Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines. Ann Surg Oncol 22(4):1207\u20131213. https:\/\/doi.org\/10.1245\/s10434-014-4115-6","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"11_CR131","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC et al (2012) Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 53(12):1863\u20131871. https:\/\/doi.org\/10.2967\/jnumed.112.105940","journal-title":"J Nucl Med"},{"issue":"12","key":"11_CR132","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","volume":"84","author":"G Vitale","year":"2001","unstructured":"Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V et al (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84(12):1586\u20131590. https:\/\/doi.org\/10.1054\/bjoc.2001.1832","journal-title":"Br J Cancer"},{"issue":"3","key":"11_CR133","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1210\/jcem.85.3.6435","volume":"85","author":"G Vitale","year":"2000","unstructured":"Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR et al (2000) Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85(3):983\u2013988. https:\/\/doi.org\/10.1210\/jcem.85.3.6435","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"11_CR134","doi-asserted-by":"publisher","first-page":"dgaa077","DOI":"10.1210\/clinem\/dgaa077","volume":"105","author":"T Vogel","year":"2020","unstructured":"Vogel T, Wendler J, Frank-Raue K, Kreissl MC, Spitzweg C, Fassnacht M et al (2020) Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology. J Clin Endocrinol Metab 105(6):dgaa077. https:\/\/doi.org\/10.1210\/clinem\/dgaa077","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"11_CR135","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"issue":"5","key":"11_CR136","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","volume":"28","author":"SA Wells Jr","year":"2010","unstructured":"Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA et al (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767\u2013772. https:\/\/doi.org\/10.1200\/JCO.2009.23.6604","journal-title":"J Clin Oncol"},{"issue":"2","key":"11_CR137","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134\u2013141. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040","journal-title":"J Clin Oncol"},{"issue":"5","key":"11_CR138","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1210\/jc.2013-2622","volume":"99","author":"SA Wells Jr","year":"2014","unstructured":"Wells SA Jr, Santoro M (2014) Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab 99(5):1543\u20131555. https:\/\/doi.org\/10.1210\/jc.2013-2622","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"11_CR139","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1089\/thy.2008.0080","volume":"18","author":"MW Wertenbroek","year":"2008","unstructured":"Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP (2008) Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 18(10):1105\u20131110. https:\/\/doi.org\/10.1089\/thy.2008.0080","journal-title":"Thyroid"},{"issue":"8","key":"11_CR140","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1210\/jc.2010-1996","volume":"96","author":"JA Wexler","year":"2011","unstructured":"Wexler JA (2011) Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab 96(8):2296\u20132307. https:\/\/doi.org\/10.1210\/jc.2010-1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"11_CR141","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1210\/jcem.81.10.8855832","volume":"81","author":"N Wohllk","year":"1996","unstructured":"Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H et al (1996) Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81(10):3740\u20133745. https:\/\/doi.org\/10.1210\/jcem.81.10.8855832","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"11_CR142","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K","volume":"73","author":"LT Wu","year":"1994","unstructured":"Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2):432\u2013436. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8293411","journal-title":"Cancer"},{"issue":"1","key":"11_CR143","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.21.01329","volume":"40","author":"B Xu","year":"2022","unstructured":"Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA et al (2022) International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 40(1):96\u2013104. https:\/\/doi.org\/10.1200\/JCO.21.01329","journal-title":"J Clin Oncol"},{"issue":"12","key":"11_CR144","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1210\/jc.2016-2815","volume":"101","author":"JY Xu","year":"2016","unstructured":"Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA et al (2016) Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Clin Endocrinol Metab 101(12):4871\u20134877. https:\/\/doi.org\/10.1210\/jc.2016-2815","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"11_CR145","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1089\/thy.2019.0579","volume":"30","author":"T Yeh","year":"2020","unstructured":"Yeh T, Yeung M, Sherman EJ, Tuttle RM, Sabra MM (2020) Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies. Thyroid 30(8):1112\u20131119. https:\/\/doi.org\/10.1089\/thy.2019.0579","journal-title":"Thyroid"},{"issue":"6","key":"11_CR146","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0039","volume":"134","author":"TW Yen","year":"2003","unstructured":"Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890\u2013899.; discussion 899-901. https:\/\/doi.org\/10.1016\/S0039","journal-title":"Surgery"},{"issue":"6","key":"11_CR147","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.surg.2011.09.043","volume":"150","author":"DT Yip","year":"2011","unstructured":"Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD et al (2011) Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery 150(6):1168\u20131177. https:\/\/doi.org\/10.1016\/j.surg.2011.09.043","journal-title":"Surgery"},{"issue":"10","key":"11_CR148","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1210\/jcem.80.10.7559902","volume":"80","author":"J Zedenius","year":"1995","unstructured":"Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B et al (1995) Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80(10):3088\u20133090. https:\/\/doi.org\/10.1210\/jcem.80.10.7559902","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Recent Results in Cancer Research","Medullary Thyroid Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-80396-3_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:59:56Z","timestamp":1742356796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-80396-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031803956","9783031803963"],"references-count":148,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-80396-3_11","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"20 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}